Sangamo | search
Click here to view Sangamo news from 60+ newspapers.
Bookmark or Share- Sangamo Therapeutics, Inc. | Pioneering Genetic CuresSangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.
- Overview | Sangamo Therapeutics, Inc.Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease.
- Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.Sangamo has a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases, focused on the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as a second undisclosed neurology target.
- News Releases | Investor Relations - Sangamo Therapeutics, Inc.- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone
- Modular Integrase (MINT) Platform - SangamoBuilding on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations ...
More
